PubMed Health⌕ Search

Biomedical subjects

N J Legg

Publications and source records attributed to N J Legg.

17 recordsLinked to original sources
PubMed1992

Langerhans' cell histiocytosis and the nervous system.

We report two cases of Langerhans' cell histiocytosis with unusual central nervous system (CNS) involvement. The first patient had behavioural disturbances, memory loss and diabetes insipidus. His response to a range of treatments was poor. The second patient presented with seizures and headaches suggestive of raised intracranial pressure. Etoposide (VP16) chemotherapy led to a dramatic clinical and radiological improvement. The various CNS manifestations of Langerhans' cell histiocytosis and their management are discussed.

Adult↗
PubMed1986

Regional cerebral blood flow and oxygen metabolism in dementia due to vascular disease.

Regional cerebral blood flow (CBF), oxygen utilisation (CMRO2) and fractional oxygen extraction (OER) were measured by positron emission tomography in patients with multi-infarct dementia. A matched reduction of both CBF and CMRO2 in the majority of patients indicated that in general, reduced cerebral perfusion in this condition is appropriate for the reduced metabolic demands of a damaged brain. Only in a very small minority of patients with dementia associated with bilateral carotid artery occlusion was CBF inappropriately low and OER raised. In these exceptional cases with critical cerebral perfusion, surgical measures to increase CBF could theoretically arrest or slow down the progress of dementia.

Brain↗
PubMed1985

The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease.

Studies performed on 18 patients with Parkinson's disease and 6 control subjects have shown that acute administration of L-DOPA in clinically effective doses gives rise to a diffuse increase in regional cerebral blood flow without accompanying stimulation of regional oxygen utilization. The data suggest that this rise in rCBF is caused by vasodilatation due to a direct action of the drug on the cerebral blood vessels. The effect of L-DOPA on rCBF did not correlate with the degree of clinical improvement seen in each patient after treatment. The therapeutic effect of L-DOPA in the brain was not reflected in any change of regional cerebral oxygen utilization as measured by our technique. We suggest that the pharmacological actions of L-DOPA in the brain take place on at least two different levels.

Adult↗
PubMed1978

Treatment of the on-off syndrome in Parkinsonism with low dose bromocriptine in combination with levodopa.

The addition of bromocriptine, given in divided doses up to 30 mg per day, to conventional anti-Parkinsonism therapy has been studied in a double-blind placebo controlled clinical trial in 11 patients with Parkinsonism with the "on-off" syndrome. Four patients withdrew because of side effects. Of the seven remaining, three had clinical benefit from bromocriptine with reduction in severity and frequency of fluctuations. There was, however, no statistically significant benefit of bromocriptine when the group as a whole was assessed in terms of severity or frequency of fluctuations measured by three different methods. The mean frequency of major fluctuations on placebo was 2.9/day and on bromocriptine 1.8/day (P less than 0.1 greater than 0.05). There appears to be a limited role for bromocriptine as additional therapy in the management of some patients with the on-off syndrome.

Antiparkinson Agents↗
PubMed1978

Blackouts.

Explore the source record for details and available documents.

Humans↗